Elizabeth Feldman Appointed Soleo Health VP Development, Industry Relations: Charged with Forging and Maintaining Pharma Manufacturer Relationships

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

November 11, 2020

Elizabeth Feldman has been appointed Soleo Health VP Development, Industry Relations.

Elizabeth Feldman will be responsible for forging and maintaining relationships with pharmaceutical manufacturers to coincide with Soleo Health’s expertise and focus on caring for complex specialty patients with rare and ultra-rare diseases.

Feldman brings more than 15 years of experience working directly with pharmaceutical manufacturers to commercialize newly launched products across multiple specialty distribution channels to her new role. Feldman was vice president, specialty distribution for Two Labs Pharma Services, a leading pharmaceutical consulting company providing a portfolio of market access, market intelligence and commercialization services to manufacturers. In this capacity, she guided various emerging specialty pharmaceutical manufacturers in the efficient launch of their products while also developing channel strategies throughout the commercialization process.

Earlier, Feldman was vice president, business development and trade relations for ASD Healthcare, the specialty distribution arm for AmerisourceBergen Corp., a global leader in pharmaceutical distribution. She was responsible for overseeing the company’s portfolio of 200+ specialty pharmaceutical products. She secured 98% of drugs launched in the specialty market within a 12-month period, effectively negotiating early-stage commercialization discussions with established and emerging manufacturers — both large and small. Many of these relationships were part of either a limited or exclusive distribution network.

Feldman’s appointment directly relates to the leadership role Soleo Health has established in the specialty pharmaceutical limited drug distribution arena, based on the capabilities of its innovative and proprietary clinical outcomes program, SoleMetrics®. At the core of several limited distribution drug manufacturer relationships the Company has forged, SoleMetrics collects and delivers real-world, insightful data regarding a drug’s clinical capabilities, derived from its patients.

Feldman commented on her joining the Company: “Soleo Health has carved a distinct market niche for itself in the complex specialty pharmaceuticals space as well as within the limited drug distribution marketplace. My new position affords me the opportunity to cultivate new manufacturer relationships while also leveraging the strong ones I have built to further cement Soleo Health’s place in future specialty drug launches.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.